治疗强直性脊柱炎的生物制剂：超越肿瘤坏死因子α拮抗剂。 - Suppr | 超能文献

Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists.

作者信息

Wendling Daniel, Prati Clément

出版信息

Joint Bone Spine. 2011 Dec;78(6):542-4. doi: 10.1016/j.jbspin.2011.05.023. Epub 2011 Jul 30.

DOI:10.1016/j.jbspin.2011.05.023

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists.治疗强直性脊柱炎的生物制剂：超越肿瘤坏死因子α拮抗剂。

Joint Bone Spine. 2011 Dec;78(6):542-4. doi: 10.1016/j.jbspin.2011.05.023. Epub 2011 Jul 30.

2

[Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab].[接受阿达木单抗治疗的强直性脊柱炎患者发生白癜风]

Ann Dermatol Venereol. 2013 Dec;140(12):801-2. doi: 10.1016/j.annder.2013.09.158. Epub 2013 Oct 14.

3

Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.强直性脊柱炎结构损伤评估的批判性评价：对治疗结果的影响

Arthritis Rheum. 2008 Mar;58(3):649-56. doi: 10.1002/art.23260.

4

BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment.强直性脊柱炎患者的BAFF水平及对抗肿瘤坏死因子治疗的反应。

Joint Bone Spine. 2013 Jul;80(4):433-4. doi: 10.1016/j.jbspin.2012.10.004. Epub 2012 Nov 16.

5

No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.强直性脊柱炎患者经肿瘤坏死因子-α 阻断治疗 6 个月和 12 个月后，动脉僵硬度无明显变化。

Rheumatology (Oxford). 2013 Jan;52(1):204-9. doi: 10.1093/rheumatology/kes272. Epub 2012 Oct 13.

6

The role of secukinumab in the treatment of ankylosing spondylitis.司库奇尤单抗在强直性脊柱炎治疗中的作用。

Immunotherapy. 2015;7(12):1241-7. doi: 10.2217/imt.15.93. Epub 2015 Nov 23.

7

[Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].[抗TNFα在类风湿关节炎和强直性脊柱炎治疗中的应用]

Presse Med. 2009 May;38(5):774-87. doi: 10.1016/j.lpm.2009.02.003. Epub 2009 Mar 26.

8

Interleukin 6 blockade in spondyloarthritis.脊柱关节炎中白细胞介素6的阻断

J Rheumatol. 2012 May;39(5):1097-8; author reply 1098. doi: 10.3899/jrheum.110955.

9

Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.强直性脊柱炎的抗肿瘤坏死因子治疗。需要指南。

Rheumatology (Oxford). 2003 Mar;42(3):490. doi: 10.1093/rheumatology/keg113.

10

Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.托珠单抗用于一名对肿瘤坏死因子拮抗剂难治的强直性脊柱炎和克罗恩病患者。

Joint Bone Spine. 2010 Dec;77(6):625-6. doi: 10.1016/j.jbspin.2010.08.004. Epub 2010 Sep 20.

引用本文的文献

1

Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies: The ESNV-SPA Study Protocol.评估迷走神经非侵入性刺激对生物疗法耐药的中轴型脊柱关节炎患者疗效的随机交叉研究：ESNV-SPA研究方案。

Front Hum Neurosci. 2021 Jun 30;15:679775. doi: 10.3389/fnhum.2021.679775. eCollection 2021.

2

Ankylosing spondylitis: from cells to genes.强直性脊柱炎：从细胞到基因

Int J Inflam. 2013;2013:501653. doi: 10.1155/2013/501653. Epub 2013 Jul 21.

3

Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.IL-6 是否为治疗抗 TNF 治疗抵抗的脊柱关节炎患者的合适靶点？一项多中心回顾性观察研究。

Arthritis Res Ther. 2012 Mar 9;14(2):R53. doi: 10.1186/ar3766.